Table 1 Nano-formulated cancer therapeutics currently on market(Adapted with permission [42])
From: Cancer nanotechnology: current status and perspectives
Product name | Composition | Indications | First approval |
|---|---|---|---|
Doxil/Caelyx | PEGylated liposomal doxorubicin | Myeloma, Kaposi’s sarcoma, breast, and ovarian cancer | US (1995) |
DaunoXome | Liposomal daunorubicin | Kaposi’s sarcoma | US (1996) |
Myocet | Liposomal doxorubicin | Breast cancer | Europe/Canada (2000) |
Abraxane | Albumin-bound paclitaxel | Breast, non-small-cell lung, and pancreatic cancer | US (2005) |
Lipusu | Liposomal paclitaxel | Breast and non-small-cell lung cancer | China (2006) |
Nanoxel | Paclitaxel micellar | Solid tumors | India (2006) |
Oncaspar | L-asparaginase conjugate | Acute lymphoblastic leukemia | US (2006) |
DepoCyt | Liposomal cytarabine | Lymphoma, Leukemia | US (1999) |
Genexol-PM | Paclitaxel micellar | Breast, non-small-cell lung, ovarian, and gastric cancer | South Korea (2007) |
Mepact | Liposomal mifamurtide | Osteogenic sarcoma | Europe (2009) |
NanoTherm | Iron oxide NPs | Brain tumors | Europe (2011) |
Marqibo | Liposomal vincristine sulfate | Acute lymphoblastic leukemia | US (2012) |
ONIVYDE | Liposomal irinotecan | Advanced pancreatic cancer | US (2015) |
DHP107 | Paclitaxel lipid NPs (oral administration) | Gastric cancer | South Korea (2016) |
Vyxeos | Liposomal daunorubicin and cytarabine | High-risk acute myeloid leukemia | US (2017) |
Apealea | Paclitaxel micellar | Ovarian, peritoneal, and fallopian tube cancer | Europe (2018) |
Hensify | Hafnium oxide NPs | Locally-advanced soft tissue sarcoma | Europe (2019) |